Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Contemporary Amperex Technology / Equity Capital Markets

Contemporary Amperex Technology (3750 HK)

<ul>
<li>Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.</li>
<li>On the IPO front, <a href="https://www.smartkarma.com/entities/shanghai-xizhi-technology-lightelligence" target="_blank" data-smartkarma-citation="entities:48061:1" rel="noopener">Shanghai Xizhi Technology (Lightelligence) (1879 HK)</a> recorded one of the highest demands yet.</li>
<li>On the placement front, <a href="https://www.smartkarma.com/entities/contemporary-amperex-technology-catl-co-limited" target="_blank" data-smartkarma-citation="entities:45179:1" rel="noopener">Contemporary Amperex Technology (CATL) (3750 HK)</a> finally got its H-share listing done.</li>
</ul>


Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.
On the IPO front, Shanghai Xizhi Technology (Lightelligence) (1879 HK) recorded one of the highest demands yet.
On the placement front, Contemporary Amperex Technology (CATL) (3750 HK) finally got its H-share listing done.


Aequitas ECM Weekly (4 May 2026)- CATL, Innolight, Lightelligence, Unimicron, Cofoe, Lenskart, Seres

<ul>
<li>Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.</li>
<li>On the IPO front, <a href="https://www.smartkarma.com/entities/victory-giant-technology-huizhou-co-ltd" target="_blank" data-smartkarma-citation="entities:48083:1" rel="noopener">Victory Giant (2476 HK)</a> managed to perform well in HK's larget listing so far this year.</li>
<li>On the placement front, <a href="https://www.smartkarma.com/entities/contemporary-amperex-technology-catl-co-limited" target="_blank" data-smartkarma-citation="entities:45179:1" rel="noopener">Contemporary Amperex Technology (CATL) (3750 HK)</a> witnessed selldowns on its A-share and H-shares line.</li>
</ul>


Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.
On the IPO front, Victory Giant (2476 HK) managed to perform well in HK's larget listing so far this year.
On the placement front, Contemporary Amperex Technology (CATL) (3750 HK) witnessed selldowns on its A-share and H-shares line.


Aequitas ECM Weekly (27 April 2026)-CATL, Victory Giant, Huaqin, MTT, Lightelligence, CICT, Sany

APAC IPOs & Placements, Aequitas Research

Akshat Shah

APAC IPOs & Placements

Zenergy Battery Technologies / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/jiangsu-zenergy-battery-technologies-group-co-ltd" target="_blank" data-smartkarma-citation="entities:43855:1" rel="noopener">Jiangsu Zenergy Battery Technologies Group(3677 HK)</a> raised US$130m from its HK IPO in April'25. The lockup on its controlling shareholders, pre-IPO investors and other shareholders is set to expire soon.</li>
<li>Zenergy is an EV and energy storage system battery manufacturer providing integrated battery solutions, encompassing battery cells, modules, packs and battery management systems dedicated to large-scale applications of electrochemical products.</li>
<li>In this note, we will talk about the lockup dynamics and possible placement.</li>
</ul>



Jiangsu Zenergy Battery Technologies Group(3677 HK) raised US$130m from its HK IPO in April'25. The lockup on its controlling shareholders, pre-IPO investors and other shareholders is set to expire soon.
Zenergy is an EV and energy storage system battery manufacturer providing integrated battery solutions, encompassing battery cells, modules, packs and battery management systems dedicated to large-scale applications of electrochemical products.
In this note, we will talk about the lockup dynamics and possible placement.


Aequitas:Zenergy Battery Technologies IPO Lockup-US$2.7bn Lockup Release but Stock Back to IPO Level

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Jingze Biopharmaceutical (Hefei) / Equity Capital Markets

Jingze Biopharmaceutical (Hefei) (JBP HK)

<ul>
<li>JZB33 is expected to have more growth potential than JZB30. However, the rhFSH market is highly competitive. JZB30/JZB33 not only need to compete with MNCs but also domestic Big Pharma.</li>
<li>The "inverted pyramid" pipeline distribution leads to a high dependence JZB30, JZB33, JZB05 for Jingze's performance growth in the next 3-5 years, thus lacking sustained innovation and growth momentum.</li>
<li>Post-Money valuation was RMB3.09 billion after Series C+ Financing. We think valuation of Jingze should be lower than Henlius, <a href="https://www.smartkarma.com/entities/chengdu-kanghong-pharmaceutical-group-a" target="_blank" data-smartkarma-citation="entities:24723:1" rel="noopener">Chengdu Kanghong </a>due to the concerns on commercialization outlook/Biosimilar VBP.</li>
</ul>


JZB33 is expected to have more growth potential than JZB30. However, the rhFSH market is highly competitive. JZB30/JZB33 not only need to compete with MNCs but also domestic Big Pharma.
The "inverted pyramid" pipeline distribution leads to a high dependence JZB30, JZB33, JZB05 for Jingze's performance growth in the next 3-5 years, thus lacking sustained innovation and growth momentum.
Post-Money valuation was RMB3.09 billion after Series C+ Financing. We think valuation of Jingze should be lower than Henlius, Chengdu Kanghong due to the concerns on commercialization outlook/Biosimilar VBP.


Pre-IPO Jingze Biopharmaceutical (Hefei) - The Concerns and the Outlook

Mabwell (Shanghai) Bioscience / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/mabwell-shanghai-bioscience-co-ltd" target="_blank" data-smartkarma-citation="entities:44225:1" rel="noopener">Mabwell (Shanghai) Bioscience (MAB HK)</a> has three commercialized products on the market, but their commercialization performance have been far lower-than-expected, leading to small revenue scale and continuously expanding losses. </li>
<li>Mabwell’s ADC technology is actually outdated. We’re not optimistic about the final efficacy of 9MW2821, which is hard to become a Best-In-Class. Other pipeline candidates need to face fierce competition.</li>
<li>Mabwell’s pipeline actually lack competitiveness in the market. Due to weak liquidity, share price of Mabwell in HK market would be traded at a discount to A shares.</li>
</ul>



Mabwell (Shanghai) Bioscience (MAB HK) has three commercialized products on the market, but their commercialization performance have been far lower-than-expected, leading to small revenue scale and continuously expanding losses. 
Mabwell’s ADC technology is actually outdated. We’re not optimistic about the final efficacy of 9MW2821, which is hard to become a Best-In-Class. Other pipeline candidates need to face fierce competition.
Mabwell’s pipeline actually lack competitiveness in the market. Due to weak liquidity, share price of Mabwell in HK market would be traded at a discount to A shares.


Pre-IPO Mabwell (Shanghai) Bioscience - The ADC Technology Is Outdated

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Mabwell (Shanghai) Bioscience (MAB HK)

Aequitas ECM Weekly (4 May 2026)- CATL, Innolight, Lightelligence, Unimicron, Cofoe, Lenskart, Seres

Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.

Sumeet Singh

Aequitas ECM Weekly (27 April 2026)-CATL, Victory Giant, Huaqin, MTT, Lightelligence, CICT, Sany

Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.

Sumeet Singh

Aequitas:Zenergy Battery Technologies IPO Lockup-US$2.7bn Lockup Release but Stock Back to IPO Level

Jiangsu Zenergy Battery Technologies raised about US$130m from its HK IPO in April 2025. The lockup on its controlling shareholders, pre-IPO...

Akshat Shah

Pre-IPO Jingze Biopharmaceutical (Hefei) - The Concerns and the Outlook

"Inverted pyramid" pipeline distribution lead to high dependence JZB30/JZB33/JZB05 for Jingze's performance growth, thus lacking sustained...

Xinyao (Criss) Wang

Pre-IPO Mabwell (Shanghai) Bioscience - The ADC Technology Is Outdated

Mabwell is struggling with lower-than-expected commercialization performance and outdated ADC technology. The pipeline lacks competitiveness,...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Aequitas ECM Weekly (4 May 2026)- CATL, Innolight, Lightelligence, Unimicron, Cofoe, Lenskart, Seres

Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.

Sumeet Singh

Aequitas ECM Weekly (27 April 2026)-CATL, Victory Giant, Huaqin, MTT, Lightelligence, CICT, Sany

Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.

Sumeet Singh

Aequitas:Zenergy Battery Technologies IPO Lockup-US$2.7bn Lockup Release but Stock Back to IPO Level

Jiangsu Zenergy Battery Technologies raised about US$130m from its HK IPO in April 2025. The lockup on its controlling shareholders, pre-IPO...

Akshat Shah

Pre-IPO Jingze Biopharmaceutical (Hefei) - The Concerns and the Outlook

"Inverted pyramid" pipeline distribution lead to high dependence JZB30/JZB33/JZB05 for Jingze's performance growth, thus lacking sustained...

Xinyao (Criss) Wang

Pre-IPO Mabwell (Shanghai) Bioscience - The ADC Technology Is Outdated

​Mabwell is struggling with lower-than-expected commercialization performance and outdated ADC technology. The pipeline lacks competitiveness,...

Xinyao (Criss) Wang

Mabwell is struggling with lower-than-expected commercialization performance and outdated ADC technology. The pipeline lacks competitiveness,...